EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Effect of upadacitinib on atopic hand eczema in patients with moderate‐to‐severe atopic dermatitis: Results from two randomized phase 3 trials

E L Simpson iD, K Rahawi, X Hu, A D Chu, C Nduaka, S Jazayeri, P Lio iD, C Lynde, M L A Schuttelaar

Journal of the European Academy of Dermatology and Venereology · 2023

DOI: 10.1111/jdv.19194 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2023. Verfasst von E L Simpson und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Oregon Health and Science University, Portland, Oregon, USA. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Eczema. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AbbVie.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Approximately 60% of patients with atopic dermatitis have involvement of the hands adding to the burden of disease.

Objective

This analysis aims to evaluate the effect of upadacitinib monotherapy on atopic hand eczema in patients with moderate‐to‐severe AD over 16 weeks in the Measure Up 1 and 2 studies.

Methods

Data from patients (ages 12–75) randomized 1:1:1 to receive upadacitinib 15 mg, 30 mg, or placebo once daily in the Measure Up 1 and 2 studies were analysed for impact on atopic hand eczema assessed using the Hand Eczema Severity Index (HECSI). The percent change from baseline in HECSI score was a prespecified additional endpoint at all visits. The proportion of patients with at least a 75% improvement in HECSI score (HECSI 75) was evaluated post hoc.

Results

Patients treated with upadacitinib 15 mg or 30 mg experienced greater improvement in HECSI score compared with placebo as early as Week 1, which was maintained through Week 16. At Week 16, the mean change from baseline in HECSI score for patients receiving upadacitinib 15 mg, 30 mg, and placebo was −68%, −74%, and −15% in Measure Up 1 and −68%, −74% and +21% (positive change indicates worsening for placebo) in Measure Up 2, respectively. A greater proportion of upadacitinib‐treated patients achieved HECSI 75 compared with placebo at all timepoints beginning at Week 1 through Week 16.

Conclusions

Upadacitinib 15 mg and 30 mg monotherapy provided rapid and sustained improvement in atopic hand eczema compared with placebo through Week 16 in patients with moderate‐to‐severe AD. At Week 16, the observed mean improvements in HECSI score in upadacitinib‐treated patients were clinically meaningful based on previous interpretability studies. These results suggest that upadacitinib may be an effective treatment option for atopic hand eczema in patients with moderate‐to‐severe AD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicEczemaHumansDouble-Blind MethodSeverity of Illness IndexTreatment OutcomeHeterocyclic Compounds, 3-Ring

Substanzen

upadacitinibHeterocyclic Compounds, 3-Ring

Autor:innen und Institutionen

  • Department of Dermatology, Oregon Health and Science University, Portland, Oregon, USA.
  • AbbVie, Inc, North Chicago, Illinois, USA.
  • Alliance Dermatology and Mohs Center PC, Phoenix, Arizona, USA.
  • Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
  • Lynde Institute of Dermatology and Probity Medical Research, Markham, Ontario, Canada.
  • Department of Dermatology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

ORCID-Profile: E L Simpson, P Lio

Förderung

  • AbbVie

Zitieren

APA

Simpson, E. L., Rahawi, K., Hu, X., Chu, A. D., Nduaka, C., Jazayeri, S., Lio, P., Lynde, C., & Schuttelaar, M. L. A. (2023). Effect of upadacitinib on atopic hand eczema in patients with moderate‐to‐severe atopic dermatitis: Results from two randomized phase 3 trials. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.19194

Vancouver

Simpson EL, Rahawi K, Hu X, Chu AD, Nduaka C, Jazayeri S, et al. Effect of upadacitinib on atopic hand eczema in patients with moderate‐to‐severe atopic dermatitis: Results from two randomized phase 3 trials. Journal of the European Academy of Dermatology and Venereology. 2023. doi:10.1111/jdv.19194

BibTeX
@article{Simpson2023,
  author = {Simpson, E L and Rahawi, K and Hu, X and Chu, A D and Nduaka, C and Jazayeri, S and Lio, P and Lynde, C and Schuttelaar, M L A},
  title = {Effect of upadacitinib on atopic hand eczema in patients with moderate‐to‐severe atopic dermatitis: Results from two randomized phase 3 trials},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2023},
  doi = {10.1111/jdv.19194}
}
Kostenlos starten →